Pharmacotherapy
A Model for Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Interacting Medications
Par Gomez-Lumbreras A, Tawfik AG, Reese T et 3 autres.
Contenu en anglais
Résumé
Introduction
Pharmacodynamic drug-drug interactions (DDI) in patients receiving oral anticoagulants (OAC) may increase the risk of gastrointestinal bleeding (GIB). The purpose of this study was to develop and validate a GIB model for patients receiving OACs.
Methods
A risk model, Drug Interactions in Oral AntiCoagulants for Risk of Gastrointestinal Bleeding (DIOAC-GIB), was developed to predict GIB based on interacting medications and other patient-specific risk factors for patients on OAC. Inputs for the model were obtained using random-effect meta-analysis or from the literature for the following attributes: exposure to nonsteroidal anti-inflammatory drugs (NSAIDs); selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors (SSRI/SNRIs); aspirin, antiplatelet medications, and proton pump inhibitors (PPIs); age; and GIB history. The model was correlated to existing OAC models (HAS-BLED and DOAC score).